Page 277 - Pagetit

NEUROSCIENCE OF PSYCHOACTIVE SUBSTANCE USE AND DEPENDENCE

biomedical research on human subjects 210, 216–217, 219–222
beneficence 217
distributive justice 217, 226
independent ethical review of risks and benefits 219
informed consent 220
non-maleficence 216–217
privacy and confidentiality 221–222, 230
recruitment of subjects 220–221
respect for autonomy 216
clinical trials 210–211, 225–227
conflicts of interests 226–227
Declaration of Helsinki 212–216
epidemiological research 209–210, 224–225
ethical analysis studies 211–218
models of dependence 231–232
prevention studies 227–231
provocation studies 223–224
public health policy 244–247
treatment studies 232–235
access to treatment 232
legally coerced treatment 232–235
types of research 209–211
vulnerable persons 222–223
identification and definition 222–223

Fluoxetine, placebo in smoking studies 181
Fos, transcriptional regulator 37–38
Frontal cortex, psychostimulant-induced levels of dopamine 178

GBR-12909 92
Genes/genetics 35–36, 125–152
alcohol use 132–136
animal models 128–130
transgenic animals 128–129
candidate gene studies 128, 140–147
confounding issues 147–148
combined risk, psychoactive substances 138–147
future directions 149–150
heritability
defined 126
estimations 127
selected substances 152
linkage studies 125, 127–128, 139
confounding issues 147–148

256

Index 256 19.1.2004, 11:52